Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Pain Therapeutics 2005' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Pain Therapeutics Inc-Therapeutic Competitors |
January 2010 | £225 | 100 % |
|
Pain Therapeutics Inc -Therapeutic Competitors |
February 2008 | £110 | 100 % |
|
Pain Therapeutics Drugs, Markets and Companies |
February 2010 | £2230 | 76 % |
|
Pain Therapeutics Inc -Detailed Product Pipeline |
February 2008 | £240 | 74 % |
|
Pain Therapeutics Inc-Financial Company Report |
March 2009 | £120 | 74 % |
|
Pain Therapeutics Inc-Detailed Product Pipeline |
January 2010 | £475 | 74 % |
|
Pain Therapeutics Inc -Financial Company Report |
February 2008 | £110 | 74 % |
|
The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape |
October 2007 | £1910 | 47 % |
|
Pain Therapeutics, Inc. - SWOT Analysis |
September 2008 | £66 | 35 % |
|
Anesiva Inc Premium Company Profile |
April 2008 | £265 | 33.5 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
February 2010 | £1780 | 31 % |
|
Treating Neuropathic Pain A Global Study of Clinical Strategies |
January 2010 | £3950 | 29 % |
|
The Global Pain Market 2008-2023 |
November 2008 | £1499 | 27.5 % |
|
Intranasal Drug Delivery US Market Trends & Analysis |
November 2009 | £1905 | 27 % |
|
Pain Therapeutics, Inc. - Financial and Strategic Analysis Review |
June 2009 | £80 | 25.9 % |
|
Avigen Inc Premium Company Profile |
April 2008 | £265 | 25 % |
|
Medicinal Use of Cannabis and Cannabinoids 1st Edition |
January 2004 | £39.95 | 24.5 % |
|
NGF Agonists and Antagonists Competitor Analysis |
May 2008 | £87 | 24.5 % |
|
Multiple Myeloma Therapeutics US Market Trends & Analysis |
November 2009 | £1905 | 22 % |
|
Renovis Premium Company Profile |
December 2007 | £265 | 22 % |
|
TorreyPines Therapeutics Inc Premium Company Profile |
April 2008 | £265 | 22 % |
|
Premium Company Profile: Endo Pharmaceuticals |
November 2007 | £265 | 21.5 % |
|
Premium Company Profile Pain Therapeutics |
October 2007 | £265 | 21 % |
|
Xenoport Inc Premium Company Profile |
December 2007 | £265 | 21 % |
|
Allergan: Pipeline , Products , Performance , Potential |
February 2008 | £595 | 20 % |
|
Labopharm Inc Premium Company Profile |
December 2007 | £265 | 18.5 % |
|
Transdermal Drug Delivery Technologies, Markets and Companies |
February 2010 | £1780 | 18 % |
|
Chronotherapeutics |
September 2003 | £75 | 17.15 % |
|
Elan Corporation, plc - SWOT Analysis |
September 2008 | £66 | 17 % |
|
5-HT7 antagonists Novel molecules for the unmet migraine prophylaxis market |
March 2003 | £330 | 16.5 % |
|
Rheumatoid Arthritis: Emerging drug discovery targets And therapeutic candidates |
October 2003 | £375 | 16.5 % |
|
Forest Laboratories, Inc. - Financial and Strategic Analysis Review |
April 2009 | £80 | 16 % |
|
Animal Therapeutics and Diagnostics |
January 2008 | £3085 | 15.5 % |
|
Cephalon - SWOT Analysis - SWOT Analysis |
October 2008 | £66 | 14 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 13.5 % |
|
Spectrum Pharmaceuticals Inc Premium Company Profile |
April 2008 | £265 | 13 % |
|
OTC market in Central and Eastern Europe 2008 Comparative analysis and development forecasts for 2008-2010 |
September 2008 | £1745 | 13 % |
|
Premium Company Profile Antares Pharma |
November 2007 | £265 | 12.5 % |
|
CNS Therapeutics A World Market Review |
November 2009 | £1905 | 12.25 % |
|
Watson Pharmaceuticals, Inc. - SWOT Analysis |
December 2008 | £66 | 12 % |
|
The Top 50 Neurodevice Companies Worldwide |
June 2009 | £305 | 12 % |
|
Mission Pharmacal Company - Strategic Analysis Review |
June 2009 | £80 | 12 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1780 | 12 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1590 | 12 % |
|
Injectable Drug Delivery: Market Impact and Industry Trends |
October 2006 | £1115 | 11.55 % |
|
Pain Management Global Trends |
November 2009 | £1905 | 11.55 % |
|
Switzerland Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 11.5 % |
|
Sepracor Inc. - Financial and Strategic Analysis Review |
June 2009 | £80 | 11 % |
|
Cephalon, Inc. - Financial and Strategic Analysis Review |
June 2009 | £80 | 11 % |
|
Pathology & Therapeutics for Pharmacists 3rd Edition |
February 2008 | £45 | 10.5 % |
|
Stakeholder Opinions: Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey |
June 2007 | £2005 | 9.8 % |
|
Launching Combination Products Brand Extension and Franchise Development Strategies |
January 2008 | £1995 | 9.8 % |
|
Peripheral Neuropathy and Neuropathic Pain, 2008 Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain |
January 2008 | £1499 | 9.8 % |
|
Disease Management |
January 2004 | £29.95 | 9.1 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 9.1 % |
|
World Market for Sexual Disorders, 2005-2012, The Traversing New Frontiers in Sexual Chemistry |
January 2006 | £795 | 9.1 % |
|
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The |
January 2007 | £1430 | 8.75 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 8.75 % |
|
Plant-Derived Drugs: Products, Technology, Applications |
June 2006 | £3085 | 8.75 % |
|
Viscosupplementation Clinical Trial Analysis |
July 2009 | £635 | 8.4 % |
|
The OTC market in Poland |
June 2006 | £1350 | 8.4 % |
|
Companion Animal Behavioral Products |
January 2007 | £895 | 8.4 % |
|
Market for Bioengineered Protein Drugs; The |
January 2007 | £3085 | 8.4 % |
|
Pfizer Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 8.05 % |
|
Botanical and Plant-Derived Drugs Global Markets |
February 2009 | £3085 | 8.05 % |
|
Valuing Pharmaceutical Innovation Pricing and Reimbursement for Innovative Therapies |
July 2008 | £1995 | 8.05 % |
|
Johnson & Johnson Medical Device Company Intelligence Report |
August 2009 | £695 | 8 % |
|
Cordis Medical Device Company Intelligence Report |
August 2009 | £195 | 8 % |
|
Pharmaceutical Regulatory Industry |
January 2006 | £3085 | 7.7 % |
|
Leading Drug Delivery Companies and Technologies Competitive landscape, company profiles and technological developments |
June 2008 | £1995 | 7.5 % |
|
Diagnostics and Therapeutics for Genetic Diseases |
April 2006 | £3085 | 7 % |
|
Rimonabant: The first of the Cannabinoid blockbusters |
June 2007 | £1499 | 7 % |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 | 7 % |
|
Emerging Opportunities with Cannabinoids |
September 2008 | £795 | 7 % |
|
Pediatric Drug Delivery Technology and Product Opportunities |
February 2009 | £1650 | 7 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 7 % |
|
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth |
October 2008 | £8000 | 7 % |
|
Nycomed Pipeline Products Performance Potential |
October 2007 | £595 | 6.65 % |
|
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market |
September 2007 | £740 | 6.65 % |
|
Lung Cancer Therapeutics |
July 2009 | £2515 | 6.65 % |
|
Pharmaceuticals in China |
February 2006 | £3055 | 6.65 % |
|
Pfizer Pipeline ,Products ,Performance ,Potential |
June 2008 | £595 | 6.3 % |
|
The World Market for Gynaecology 2007-2017 |
September 2007 | £3200 | 6.3 % |
|
Scrip R&D Databook 2006 |
January 2006 | £1295 | 6.3 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 5.95 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 5.6 % |
|
OTC market in Central and Eastern Europe 2009 Comparative analysis and development forecasts for 2009-2011 |
August 2009 | £2180 | 5.6 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
October 2005 | £1270 | 5.25 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 | 5.25 % |
|
Dermatological and Cosmeceutical Development: Absorption Efficacy and Toxicity |
August 2007 | £130 | 5.25 % |
|
Spinal Surgery |
July 2009 | £2515 | 5.25 % |
|
Adolor Corp. - Financial and Strategic Analysis Review |
June 2009 | £80 | 4.9 % |
|
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking |
June 2007 | £1900 | 4.9 % |
|
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking |
June 2007 | £1900 | 4.9 % |
|
Virtual Reality Applications in Healthcare U.S. Market |
August 2007 | £2545 | 4.9 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £8000 | 4.9 % |
|
New Therapeutics and Diagnostics for Women’s Disorders |
May 2005 | £3085 | 4.9 % |
|
Emerging Technologies in Spinal Motion Preservation |
October 2006 | £1295 | 4.9 % |
|
United States Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2012 |
September 2008 | £1910 | 4.9 % |
|
Cell Therapy Markets |
July 2007 | £2165 | 4.9 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 4.9 % |
|
The Future of The Diabetes Care Devices Market to 2016 The Key Demand Drivers Remain Intact |
January 2010 | £2230 | 4.55 % |
|
Cancer Therapeutics: The Worldwide Market The Worldwide Market , 2nd Editon |
February 2007 | £2545 | 4.55 % |
|
World Gastrointestinal Disorders Market 2006-2011; The |
January 2006 | £1799 | 4.2 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
February 2010 | £2230 | 4.2 % |
|
Radiation-based Therapy and Therapeutic Imaging |
May 2005 | £3085 | 4.2 % |
|
Pharma R&D Fact Book, The 2006 |
November 2007 | £495 | 3.85 % |
|
U.S. Market for Gastrointestinal Pharmaceuticals |
September 2005 | £3085 | 3.85 % |
|
Medtronic Medical Device Company Intelligence Report |
September 2006 | £495 | 3.85 % |
|
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
December 2006 | £6000 | 3.5 % |
|
RNAi Technologies, Markets and Companies |
February 2010 | £2230 | 3.5 % |
|
The 100 Biggest Acute Hospitals In Europe |
January 2009 | £605 | 3.15 % |
|
Launch Strategies - Analyzing Market Trends and Regulatory Impacts |
August 2007 | £8010 | 3.15 % |
|
Hot and Cold Therapy Packs Global Market Trends |
November 2009 | £1905 | 3.15 % |
|
Human Vaccines Global Market Opportunities |
November 2009 | £1905 | 3.15 % |
|
The Global OTC Pharmaceutical Market 2009-2024 |
May 2009 | £1499 | 3.15 % |
|
Gene Therapy Technologies, Markets and Companies |
February 2010 | £2865 | 3.15 % |
|
Personalized Medicine Scientific & Commercial Aspects |
February 2010 | £2545 | 2.8 % |
|
Why Do Drugs Fail? |
November 2008 | £995 | 2.8 % |
|
Medical Imaging: Reagents and Analysis Tools |
December 2006 | £3085 | 2.8 % |
|
Pediatric Drugs: the Worldwide Market 3rd Edition |
December 2007 | £2545 | 2.8 % |
|
Aesthetic Devices Clinical Trial Analysis |
July 2009 | £635 | 2.8 % |
|
Generic League Market Analysis and Forecasts, 2007-2012, 2017 & 2022 |
February 2008 | £1999 | 2.45 % |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £6495 | 2.45 % |
|
US Anesthesia and Respiratory Devices Market Analysis & Forecasts to 2015 |
March 2009 | £2230 | 2.45 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 2.45 % |
|
US Anesthesia and Respiratory Devices Market Analysis & Forecasts to 2015 |
March 2009 | £2230 | 2.45 % |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £6000 | 2.1 % |
|
Nanobiotechnology Applications, Markets and Companies |
February 2010 | £2865 | 2.1 % |
|
United States Anesthesia and Respiratory Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £1590 | 2.1 % |
|
United Sates Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £1590 | 1.75 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £6000 | 1.75 % |
|
Cell Therapy Technologies, Markets and Companies |
February 2010 | £3185 | 1.75 % |
|
The US Pharmaceutical Market 2009-2024 |
November 2009 | £1499 | 1.4 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 1.4 % |
|
Biomarkers Technologies, Markets and Companies |
February 2010 | £2865 | 1.4 % |
